H. van Slooten

Morphologic characteristics of benign and malignant adrenocortical tumors

H. van Slooten, Aard Schaberg, D. Smeenk et al. · Cancer · 1985 · 330 citations · Full text

Medicine, Endocrinology, Pathology +17

The treatment of adrenocortical carcinoma with o,p′-DDD: Prognostic simplications of serum level monitoring

H. van Slooten, A. J. Moolenaar, A.P. van Seter et al. · European Journal of Cancer and Clinical Oncology · 1984 · 196 citations

Medicine, Endocrinology, Oncology +11

Patients’ preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?

S.J.T. Jansen, J. Kievit, M. Nooij et al. · British Journal of Cancer · 2001 · 100 citations · Full text

Medicine, Oncology, Breast Oncology +14

Blood levels of o,p′-DDD following administration in various vehicles after a single dose and during long-term treatment

A. J. Moolenaar, H. van Slooten, Arnoud P. van Seters et al. · Cancer Chemotherapy and Pharmacology · 1981 · 73 citations

Pharmacy, Pharmacokinetics, Pharmacology +3

CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma.

H. van Slooten, A.T. van Oosterom · PubMed · 1983 · 52 citations

Medicine, Oncology, Pharmacology +15